ANI Pharmaceuticals reports positive uveitis trial results
ANI Pharmaceuticals (NASDAQ:ANIP) reported positive six-month topline results from the Phase 4 SYNCHRONICITY trial evaluating fluocinolone acetonide intravitreal implant 0.18 mg in 108 patients with chronic non-infectious uveitis affecting the posterior segment.











